Table 4.
One-year Excess Hazard Ratios (EHR) and 95% confidence intervals (95%CI) according to implementation of standardised cancer patient pathways (CPP) in Denmark
| Before CPP | During CPP | After CPP | ||||||
|---|---|---|---|---|---|---|---|---|
| Total | CPP referred | |||||||
| EHR | (95%CI) | EHR | (95%CI) | EHR | (95%CI) | EHR | (95%CI) | |
| CRC | 1.02 | (0.69;1.51) | 1.04 | (0.80;1.34) | 1 | ref | 1.15 | (0.76;1.75) |
| Lung | 1.11 | (0.90;1.37) | 1.01 | (0.87;1.17) | 1 | ref | 0.73 | (0.57;0.94) |
| Melanoma | 1.13 | (0.21;5.79) | 0.84 | (0.24;2.94) | 1 | ref | 0.62 | (0.09;4.35) |
| Head & neck | 1.74 | (0.82;3.67) | 1.03 | (0.55;1.94) | 1 | ref | 1.22 | (0.44;3.33) |
| Upper GI | 1.24 | (0.97;1.59) | 0.94 | (0.78;1.13) | 1 | ref | 0.96 | (0.68;1.34) |
| Gynaecological | 2.60 | (1.37;4.94) | 1.29 | (0.75;2.22) | 1 | ref | 0.47 | (0.11;1.97) |
| Urinary system | 1.59 | (0.96;2.66) | 0.95 | (0.64;1.41) | 1 | ref | 0.51 | (0.25;1.06) |
| Total | 1.25 | (1.10;1.43) | 0.99 | (0.90;1.10) | 1 | ref | 0.86 | (0.73;1.01) |
Last column shows EHRs and 95%CIs between referral route (CPP or not) in 2010
EHRs adjusted for sex, age, tumour stage, comorbidity (Charlson’s Comorbidity Index), educational level, disposable income, diagnosis (total only) and ovarian cancer (gynaecological cancers only). Estimates in bold indicate a statistical significance of p < 0.05 or less